Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials

Jakafi (ruxolitinib) - Incyte

Ojjaara (momelotinib) - GSK

https://www.sciencedirect.com/science/article/abs/pii/S2152265026023244

Pankit Vachhani MD 1; Alessandro Lucchesi MD 2; Andrew Charles Perkins MD 3; Jasmine Sahni PharmD 4; Mahshid Azimi PharmD 4; Jessica Lim MA 4; Shiyuan Zhang MSc 4; Dwaipayan Patnaik MD 5; Jeanne M Palmer MD 6; Prithviraj Bose MD 7

Sep 1, 2026